All blog posts
Total 303 results for
Showing 24 out of 303 results
27 4月 2026
The EU Pharma Package is finally here – here's the settled position on key areas
01 4月 2026
IP Australia releases consultation paper on IP reforms
12 3月 2026
Snapshot: Key European pharma regulatory, IP and competition developments from 2025 for the pharmaceutical sector
11 2月 2026
Supreme Court overrules Aerotel and aligns UK approach to AI and computer-implemented inventions with the EPO
09 2月 2026
Preliminary injunctions and "unreasonable delay" at the UPC - Key Takeaways from recent UPC PI decisions
19 1月 2026
Where is the UPC after two and a half years - and what to expect in 2026?
23 12月 2025
Mixing it up: The end of the line for patent term extensions for formulation patents in Australia
15 12月 2025
A new era for EU pharmaceutical law: political agreement reached on the reform
09 12月 2025
Preserving the status quo: Boehringer Ingelheim awarded interim injunction
04 12月 2025
The UPC confirms the applicable doctrine of equivalence test when parties cannot agree one and applies a form of file wrapper estoppel on literal infringement claims
02 12月 2025
UPC holds CE marking approval is evidence of imminent infringement and starts the clock running where considering any (unreasonable) delay in a PI application
28 11月 2025
Accounting for profits – interest and double recovery in Lufthansa v Astronics and Panasonic
Showing 24 out of 303 results
View moreKey contacts
Rebekah Gay
Partner, Head of Intellectual Property, Sydney
Laura Orlando
Managing Partner, Milan Office, Milan
Sue Gilchrist
Consultant, Sydney
Peng Lei
Partner, Kewei, Mainland China and Shanghai
Alexandra Neri
Partner, Paris
Dr Ina vom Feld
Partner, Germany
Sebastian Moore
Partner, Head Intellectual Property, London and Milan
Rachel Montagnon
Knowledge Counsel, London